» Articles » PMID: 31775680

Clinical and Imaging Features of Myeloid Sarcoma: a German Multicenter Study

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2019 Nov 29
PMID 31775680
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Myeloid sarcoma (MS), also known as chloroma, is an extramedullary manifestation of malignant primitive myeloid cells. Previously, only small studies investigated clinical and imaging features of MS. The purpose of this study was to elucidate clinical and imaging features of MS based upon a multicenter patient sample.

Methods: Patient records of radiological databases of 4 German university hospitals were retrospectively screened for MS in the time period 01/2001 and 06/2019. Overall, 151 cases/76 females (50.3%) with a mean age of 55.5 ± 15.1 years and 183 histopathological confirmation or clinically suspicious lesions of MS were included into this study. The underlying hematological disease, localizations, and clinical symptoms as well as imaging features on CT and MRI were investigated.

Results: In 15 patients (9.9% of all 151 cases) the manifestation of MS preceded the systemic hematological disease. In 43 cases (28.4%), first presentation of MS occurred simultaneously with the initial diagnosis of leukemia, and 92 (60.9%) patients presented MS after the initial diagnosis. In 37 patients (24.5%), the diagnosis was made incidentally by imaging. Clinically, cutaneous lesions were detected in 35 of 151 cases (23.2%). Other leading symptoms were pain (n = 28/151, 18.5%), neurological deficit (n = 27/151, 17.9%), swelling (n = 14/151, 9.3%) and dysfunction of the affected organ (n = 10/151, 6.0%). Most commonly, skin was affected (n = 30/151, 16.6%), followed by bone (n = 29/151, 16.0%) and lymphatic tissue (n = 21/151, 11.4%). Other localizations were rare. On CT, most lesions were homogenous. On T2-weighted imaging, most of the lesions were hyperintense. On T1-weighted images, MS was hypointense in n = 22/54 (40.7%) and isointense in n = 30/54 (55.6%). A diffusion restriction was identified in most cases with a mean ADC value of 0.76 ± 0.19 × 10 mm/s.

Conclusions: The present study shows clinical and imaging features of MS based upon a large patient sample in a multicenter design. MS occurs in most cases meta-chronous to the hematological disease and most commonly affects the cutis. One fourth of cases were identified incidentally on imaging, which needs awareness of the radiologists for possible diagnosis of MS.

Citing Articles

Diagnostic Approaches in Myeloid Sarcoma.

Patkowska E, Krzywdzinska A, Solarska I, Wojtas M, Prochorec-Sobieszek M Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996833 PMC: 11853749. DOI: 10.3390/cimb47020111.


Two cases of myeloid sarcoma of the mediastinum.

Irie S, Inoue A, Nakamura T, Kobayashi Y, Yamaguchi T, Aoki R Radiol Case Rep. 2025; 20(4):2063-2069.

PMID: 39944162 PMC: 11815513. DOI: 10.1016/j.radcr.2025.01.035.


Cervical myeloid sarcoma as an initial clinical manifestation: Four case reports.

Li J, Wang X, Fu J, Zhang D World J Clin Oncol. 2024; 15(10):1324-1332.

PMID: 39473855 PMC: 11514511. DOI: 10.5306/wjco.v15.i10.1324.


A Rare Case of Partial Small Bowel Obstruction Secondary to Intestinal Myeloid Sarcoma.

Barnard P, Mouline O Cureus. 2024; 16(1):e52956.

PMID: 38283782 PMC: 10810725. DOI: 10.7759/cureus.52956.


De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.

Gu Y, Zheng H, Mo S, Guo T, Chen L, Yang J BMC Womens Health. 2023; 23(1):141.

PMID: 36978050 PMC: 10053749. DOI: 10.1186/s12905-023-02278-3.


References
1.
Liu P, Ishimaru T, McGregor D, Okada H, Steer A . Autopsy study of granulocytic sarcoma (chloroma) in patients with myelogenous leukemia, Hiroshima-Nagasaki 1949-1969. Cancer. 1973; 31(4):948-55. DOI: 10.1002/1097-0142(197304)31:4<948::aid-cncr2820310428>3.0.co;2-n. View

2.
Chaudhry A, Gul M, Chaudhry A, Dunkin J . Qualitative Assessment of Diffusion Weighted Imaging and Susceptibility Weighted Imaging of Myeloid Sarcoma Involving the Brain. J Comput Assist Tomogr. 2015; 40(1):61-6. DOI: 10.1097/RCT.0000000000000337. View

3.
Kawamoto K, Miyoshi H, Yoshida N, Takizawa J, Sone H, Ohshima K . Clinicopathological, Cytogenetic, and Prognostic Analysis of 131 Myeloid Sarcoma Patients. Am J Surg Pathol. 2016; 40(11):1473-1483. DOI: 10.1097/PAS.0000000000000727. View

4.
Hou X, Du L, Yu H, Zhang X . Use of magnetic resonance imaging for diagnosis and after treatment of patients with myeloid sarcoma of the brain. Oncotarget. 2017; 8(60):102581-102589. PMC: 5731983. DOI: 10.18632/oncotarget.21905. View

5.
Wilson C, Medeiros L . Extramedullary Manifestations of Myeloid Neoplasms. Am J Clin Pathol. 2015; 144(2):219-39. DOI: 10.1309/AJCPO58YWIBUBESX. View